Notch versus the proteasome: What is the target of γ-secretase inhibitor-I?

Breast Cancer Research

Volumn 11, Issue 5, 2009, Pages

  Clementz, Anthony G ^a   Osipo, Clodia ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DAPT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JAGGED1; L 685458; MELPHALAN; NOTCH RECEPTOR; PROGESTERONE RECEPTOR; PROTEASOME; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; Z LEUCYLLEUCYLEUCINE CHO; BENZYLOXYCARBONYL LEUCYL LEUCYL NORLEUCINAL; BENZYLOXYCARBONYL-LEUCYL-LEUCYL-NORLEUCINAL; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN; OLIGOPEPTIDE; SECRETASE; GAMMA SECRETASE INHIBITOR 1; NOTCH1 RECEPTOR;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CONTACT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL VIABILITY; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; MITOSIS INHIBITION; PROTEIN DEGRADATION; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; NOTE; TUMOR CELL LINE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER CELL LINE; CANCER MORTALITY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; NONHUMAN; OVERALL SURVIVAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LEUPEPTINS; OLIGOPEPTIDES; RECEPTORS, NOTCH;

EID: 77449108430     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2407     Document Type: Editorial

References (12)

1. Han J, Ma I, Hendzel MJ, Allalunis-Turner J. The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition. Breast Cancer Res 2009, 11:R57. 2750119, 19660128, 10.1186/bcr2347.
2. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004, 11:497-522. 10.1677/erc.1.00758, 15369451.
3. Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 2001, 6:23-36. 10.1023/A:1009512414430, 11467450.
4. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65:8530-8537. 10.1158/0008-5472.CAN-05-1069, 16166334.
5. Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Velde H, Regierer A, Possinger K. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008, 19:871-876. 10.1093/annonc/mdm569, 18209010.
6. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007, 99:616-627. 10.1093/jnci/djk133, 17440163.
7. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 2009, 69:5015-5022. 10.1158/0008-5472.CAN-08-3478, 19491273.
8. Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, Coombes RC. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009, 100:1879-1888. 10.1038/sj.bjc.6605034, 19513078.
9. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 2009, 15:2010-2021. 10.1158/1078-0432.CCR-08-1327, 19276287.
10. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008, 68:5226-5235. 10.1158/0008-5472.CAN-07-5744, 18593923.
11. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27:5124-5131. 10.1038/onc.2008.226, 18758481.
12. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032. 10.1038/onc.2008.149, 18469855.